Compare LYTS & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LYTS | PRME |
|---|---|---|
| Founded | 1976 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 925.2M | 536.4M |
| IPO Year | 1994 | 2022 |
| Metric | LYTS | PRME |
|---|---|---|
| Price | $26.43 | $3.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $27.50 | $7.56 |
| AVG Volume (30 Days) | 518.1K | ★ 2.9M |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.87% | N/A |
| EPS Growth | N/A | ★ 18.18 |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $573,377,000.00 | $4,632,000.00 |
| Revenue This Year | $16.20 | $7.06 |
| Revenue Next Year | $27.71 | $47.01 |
| P/E Ratio | $55.83 | ★ N/A |
| Revenue Growth | 22.09 | ★ 55.28 |
| 52 Week Low | $16.92 | $2.28 |
| 52 Week High | $27.36 | $6.94 |
| Indicator | LYTS | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 61.56 | 53.56 |
| Support Level | $21.96 | $3.16 |
| Resistance Level | N/A | $3.68 |
| Average True Range (ATR) | 1.13 | 0.25 |
| MACD | 0.11 | 0.04 |
| Stochastic Oscillator | 79.85 | 65.56 |
LSI Industries Inc provides corporate visual image solutions to the petroleum and convenience store industry. The company's operating segments include Lighting and Display Solutions. It generates maximum revenue from the Display solutions segment. Lighting Segment manufactures and markets outdoor and indoor lighting and lighting controls for the commercial, industrial, and multi-site retail markets, including the petroleum/convenience store, quick-service, and automotive markets. The Display Solutions Segment manufactures, sells, and installs exterior and interior visual image and display elements, including printed graphics, structural graphics, digital signage, menu board systems, display fixtures, refrigerated displays, and custom display elements.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.